R-BENDA PROTOKOLÜ

Kaynaklar:

1- Rummel, M. J., N. Niederle, G. Maschmeyer, et al. 2013. "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial." Lancet 381(9873):1203-1210.

2- Flinn, I. W., R. van der Jagt, B. S. Kahl, et al. 2014. "Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study." Blood 123(19):2944-2952.

3- Marcus, R., A. Davies, K. Ando, et al. 2017. "Obinutuzumab for the First-Line Treatment of Follicular Lymphoma." N Engl J Med 377(14):1331-1344.

4- Hiddemann, W., A. Barbui, M. Canales et al. 2018. "Immunochemotherapy with Obinutuzumab or Rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety". J Clin Oncol. 2018 Aug 10;36(23):2395-2404

5- Cheson, B. D., R. I. Fisher, S. F. Barrington, et al. 2014. "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification." J Clin Oncol 32(27):3059-3068.

6-Anne-Sophie Michallet, et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr; 103(4): 698–706.